Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Key Takeaway: Organon and Samsung Bioepis have expanded their agreement to commercialize PYZCHIVA®, a biosimilar referencing STELARA® (ustekinumab), in Canada. This collaboration aims to enhance the availability of this treatment in the Canadian market. Further details regarding the terms of the agreement or expected timelines were not disclosed.